Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM)

Dante Pennipede, Ghulam Rehman Mohyuddin, Ryan Hawkins, Siddhartha Ganguly, Leyla Shune, Nausheen Ahmed, Meera Mohan, Wei Cui, Zahra Mahmoudjafari, Joseph McGuirk, Shebli Atrash, Al Ola Abdallah

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple-class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of the KCd on triple-class RRMM patients at our institution. Patients and Methods: Twenty-three patients with triple-class RRMM treated with KCd between June 2017 and October 2020 were included in our analysis. The regimen KCd consisted of 28 days cycles of carfilzomib 20/36 mg/m2 IV on days 1, 2, 8, 9, 15, and 16, cyclophosphamide 300 mg/m2 IV weekly, and dexamethasone (20-40) mg orally weekly. Results: Patients received a median of 6 (3-10) prior regimens. The median number of cycles administered was 4 (1-11) cycles. Overall response rate was 52%, 6 patients (26%) achieved very good partial response (VGPR), 6 patients (26%) achieved partial response (PR), and 5 patients (22%) achieved stable disease (SD). Progression-free survival (PFS) and Overall-survival (OS) were 4 and 11.9 months, respectively. There was no reported treatment-related mortality. The most common grade ≥3 adverse events were neutropenia (26%), thrombocytopenia (56.5%), and anemia (56.5%). Conclusions: KCd showed clinically meaningful efficacy and manageable safety profile in patients with triple-class RRMM in real-world.

Original languageEnglish (US)
JournalEuropean Journal of Haematology
DOIs
StateAccepted/In press - 2021

Keywords

  • carfilzomib
  • cyclophosphamide
  • multiple myeloma
  • triple-class refractory myeloma

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM)'. Together they form a unique fingerprint.

Cite this